Federal Policy
CMS Launches Medicare GLP-1 Bridge Program with Fixed-Cost Access
The Centers for Medicare & Medicaid Services launched its Medicare GLP-1 Bridge program on July 1, 2026, offering select beneficiaries fixed-cost access to GLP-1 medications including Foundayo and Wegovy. The program arrives as GLP-1 use among US adults reached 11% in 2026, up from 3% in 2024, according to a July 7 Gallup poll. The new Medicare benefit structure establishes precedent for coverage of anti-obesity medications that could influence Medicaid managed care pharmacy benefits and prior authorization protocols. Medicaid MCOs should monitor whether states adopt similar fixed-cost or expanded coverage models for their programs.
Why it mattersThe Medicare GLP-1 Bridge program creates federal precedent for anti-obesity medication coverage that may pressure state Medicaid programs to expand formulary access and revise utilization management protocols for high-cost weight loss drugs.